Preclinical studies in NAFLD have demonstrated that a reduction in G protein-coupled glucagon receptor (GCGR) signaling results in an increase of hepatic fat content (37, 38). Here, GCGR is linked to metabolic dysfunction-associated steatotic liver disease.